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Abstract
Objectives
Currently used risk scores for type 2 diabetes mellitus (T2DM) clearly underestimate cardio-
vascular risk in type 1 diabetes (T1DM). Hence, there is a need to develop novel and specific
risk-estimation tools for this population. We aimed to assess the relationship between the
Steno Type 1 Risk Engine (ST1RE) and arterial stiffness (AS), and to identify potential cut-
off points of interest in clinical practice.
Design and methods
A total of 179 patients with T1DM (50.8% men, mean age 41.2±13.1 years), without estab-
lished cardiovascular disease, were evaluated for clinical and anthropometric data (includ-
ing classical cardiovascular risk factors), and AS measured by aortic pulse-wave velocity
(aPWV). The ST1RE was used to estimate 10-year cardiovascular risk and patients were
classified into 3 groups: low- (<10%; n = 105), moderate- (10–20%; n = 53) and high-risk
(�20%; n = 21).
Results
When compared with the low- and moderate-risk groups, patients in the high-risk group
were older, had higher prevalence of hypertension, dyslipidemia and insulin-resistance, and
had higher body-mass index and HbA1c. aPWV increased in parallel with estimated cardio-
vascular risk (6.4±1.0, 8.4±1.3 and 10.3±2.6m/s; p<0.001). As an evaluation of model
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performance, the C-statistic of aPWV was 0.914 (95% confidence interval [CI]:0.873–0.950)
for predicting moderate/high-risk and 0.879 (95%CI:0.809–0.948) for high-risk, according to
the ST1RE. The best cut-off points of aPWV were 7.3m/s (sensitivity:86%, specificity:83%)
and 8.7m/s (sensitivity:76%, specificity:86%) for moderate/high- and high-risk, respectively.
Conclusions
AS is highly correlated with the scores obtained from the ST1RE. We have identified two
cut-off points of AS that can clearly discriminate moderate/high- and high-risk T1DM
patients, which could be of great value in clinical practice.
Introduction
Cardiovascular disease (CVD) is the leading cause of death in patients with type 1 diabetes
mellitus (T1DM) [1], with coronary artery disease (CAD) as the principal manifestation [2].
Indeed, the relative risk of death from CAD in T1DM can be ten times greater than that in the
non-diabetic population, especially in women, and it is even greater than the relative risk in
type 2 diabetes (T2DM) [1, 3]. Moreover, T1DM causes a life expectancy loss of about 11 years
for men and 13 years for women, with the largest percentage of the estimated loss in life expec-
tancy related to ischemic heart disease (up to one-third) [4].
Arterial stiffness is an early indicator of arteriosclerosis and vascular damage [5] and,
accordingly, it´s analysis could provide insights into arteriosclerotic mechanisms long before
any cardiovascular event occurs. Arterial stiffness predicts cardiovascular events indepen-
dently of classical cardiovascular risk factors in several populations [6–8], and its estimation
has been demonstrated to improve cardiovascular risk prediction beyond the Framingham
Risk Score [9, 10]. However, prospective studies assessing the prognostic value of aortic pulse
wave velocity (aPWV), a marker of arterial stiffness, in subjects with T1DM are lacking.
Several risk scores have been developed to predict CVD both in the general population and
specifically in patients with T2DM. However, neither general (Framingham Risk Score) nor
T2DM (UKPDS Risk Engine) risk algorithms are sufficiently robust for risk prediction in
T1DM [11, 12]. Accordingly, the Scientific Statement from the American Heart Association
and the American Diabetes Association on CVD points to the need for novel risk-estimation
tools for better prediction of cardiovascular events in T1DM and suggests the use of models
specifically obtained from T1DM cohorts [2], such as the Steno Type 1 Risk Engine (ST1RE).
Against this background, the aims of the present study were to assess the relationship
between the ST1RE and preclinical atherosclerosis measured as arterial stiffness, and to iden-
tify potential cut-off points of interest in clinical practice.
Material and methods
Study subjects
One hundred and seventy-nine patients aged 18–65 years, with T1DM and without established
CVD were included in the study. Patients were consecutively recruited from our outpatient
clinic from November 2008 to February 2014. T1DM was defined as an onset of diabetes
before the age of 36 years and undetectable fasting levels of serum C-peptide (<0.6 ng/mL).
Exclusion criteria included the following: i) presence of previous clinical CVD (CAD, cerebro-
vascular disease or peripheral artery disease) based on clinical registers, previous personal
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history of CVD and/or the presence of suggestive symptoms, ii) abnormal resting ECG, iii)
any other acute/chronic condition associated with an inflammatory response (e.g., acute or
chronic inflammatory or infectious diseases), iv) use of anti-inflammatory drugs in the previ-
ous 6 months, v) malignant disease in the previous 5 years (except basal cell carcinoma), vi)
hospitalization in the previous 2 months, vii) arrhythmia (other than atrial premature com-
plex), and viii) pregnancy. The study protocol was approved by our hospital ethics committee
(Parc Taulı´ Research Ethics Committee) and was conducted in accordance with the Declara-
tion of Helsinki. All subjects gave their written informed consent before participating in the
study.
Study design
All subjects underwent standard anamnesis and physical examination, as previously described
[13, 14]. The following information was recorded using a predefined standardized form: age,
sex, diabetes duration, family history of premature CVD (defined as CVD occurring before the
age of 55 in males and 65 in female first-degree relatives), physical activity (International Phys-
ical Activity Questionnaire) [15], active smoking, alcohol intake, insulin dose, and the use of
any other medication. Body weight, height, and waist and hip circumference were registered.
Systolic and diastolic blood pressure (SBP and DBP, respectively) were measured and mean
arterial pressure (MAP) was calculated as 1/3 SBP + 2/3 DBP. Venous blood samples were
taken after an overnight fast and complete blood counts, fasting plasma glucose, HbA1c, creati-
nine and lipid profile were determined. Hypertension was defined as BP >140/90 [16] and/or
taking antihypertensive drugs. Dyslipidemia was defined as having concentrations of total cho-
lesterol>5.2mmol/L, triglycerides >1.7 mmol/L, HDL-cholesterol <1.03mmol/L, LDL- cho-
lesterol>3.4mmol/L [17] and/or receiving drug treatment for dyslipidemia.
Laboratory analyses
HbA1c was determined by high-performance liquid chromatography (Menarini Diagnostics,
Firenze, Italy). Total serum cholesterol, triglycerides and HDL-cholesterol were measured
using standard enzymatic methods. LDL-cholesterol was estimated with the Friedewald for-
mula [18].
Insulin resistance
To estimate insulin resistance, we used the formula proposed by Williams et al. for patients
with T1DM [19], subsequently adapted for the use of HbA1c rather than HbA1 by Kilpatrick
et al. for its use in the DCCT/EDIC cohort [20]. It yields an estimate of the glucose disposal
rate (eGDR), taking into account glycemic control, waist-to-hip ratio (WHR) and blood pres-
sure (eGDR = 24.31–12.22 × [WHR] - 3.29 × [hypertension 0 = No; 1 = Yes] - 0.57 × [HbA1c])
[20]. The formula was validated against euglycemic-hyperinsulinemic clamp in a group of
patients with T1DM clinically similar to those evaluated in the present study. Lower eGDR val-
ues reflect higher insulin resistance levels.
Assessment of microvascular complications
Peripheral polyneuropathy was assessed through a previously described two-step protocol
combining the 15-item MNSI questionnaire and a physical examination [21]. The same oph-
thalmologist evaluated the presence and degree of diabetic retinopathy in all patients, who
were then classified into the following three groups according to the degree of retinopathy: no
retinopathy, non-proliferative retinopathy, or proliferative retinopathy. Nephropathy was
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assessed by the measurement of the urinary albumin/creatinine ratio. Subjects with a ratio
greater than 3.4 mg/mmol [22], or previously treated with converting enzyme inhibitors or
angiotensin receptor blockers (for microalbuminuria or macroalbuminuria), were classified as
having diabetic nephropathy.
Measurement of arterial stiffness
We measured aPWV, a gold standard for measuring arterial stiffness, as recommended by cur-
rent international consensus [23]. The method has been previously described in detail [14].
Briefly, aPWV was determined by sequential applanation tonometry using a Millar tonometer
(SPC-301, Millar Instruments, Houston, TX, USA) at the carotid and femoral arteries, gated to
three-lead electrocardiography using the SphygmoCor system (AtCor Medical Pty Ltd., West
Ryde (Sydney), NSW, Australia). Those aPWV recordings not satisfying the automatic quality
controls specified by the SphygmoCor software were rejected. The mean of two aPWV mea-
surements was used for each subject for all calculations. Data were available for all the partici-
pants included in the study.
Steno Type 1 Risk Engine
Our data were used to calculate the 10-year probability of CVD according to the ST1RE [12].
This score considers the following variables: age, gender, smoking habit, exercise, T1DM dura-
tion, systolic blood pressure, LDL-cholesterol, HbA1c, renal function and micro-/macroalbu-
minuria. Based on the score obtained, patients were classified into 3 groups: low- (<10%;
n = 105), moderate- (10–20%; n = 53) and high-risk (�20%; n = 21).
Statistical analyses
All data were tested for normality using the Shapiro-Wilk test. Data are presented as percent-
age, mean (standard deviation) for normally distributed quantitative variables, or median
(interquartile range) for non-normally distributed quantitative variables. One-way analysis of
variance (ANOVA) or the Kruskal-Wallis test was used for comparisons between groups of
normally and non-normally distributed quantitative variables, as needed. The Bonferroni pro-
cedure (parametric) and the Dunn’s test (non-parametric) were used for post hoc analyses for
multiple comparisons. We tested aPWV discrimination using the C-statistic derived from the
logistic regression models. Receiver-operating characteristic (ROC) curves were developed to
represent the prediction of 10-year probability of CVD risk (based on the equation obtained
from ST1RE), in which sensitivity is plotted as a function of 1-specificity, for both moderate/
high- and high-risk groups. The best aPWV cut-off point was selected based on the Youden
index calculation. Two-tailed p-values <0.05 were considered statistically significant. All cal-
culations were made using STATA v.13.1 for Mac (StataCorp LP, College Station, TX, USA).
Results
A total of 179 patients with T1DM were included. The main clinical and analytical characteris-
tics of the study population, stratified by CVD risk (low, moderate and high), are shown in
Table 1. When compared with the low- and moderate-risk groups, patients in the high-risk
group were older and had a higher prevalence of hypertension and dyslipidemia. They also
had a higher body-mass index (BMI), higher insulin resistance, worse glycemic control and
higher prevalence of microvascular complications. aPWV increased in parallel with estimated
cardiovascular risk (Fig 1, panel A).
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Table 1. Clinical and metabolic characteristics of patients with type 1 diabetes stratified by 10-year CVD risk according to the Steno Type 1 Risk Engine.
Whole population (n = 179) Low-risk (n = 105) Moderate-risk (n = 53) High-risk (n = 21) p for trend
Clinical characteristics
Age (yrs.) 41.2 (13.1) 32.5 (8.3) 50.8 (6.0)� 60.7 (6.6)†,‡ <0.001
Gender (male/female), n 91/88 52/53 29/24 10/11 NS
Current smokers, n (%) 57 (31.8) 31.0 (29.5) 21 (39.6) � 5 (23.8) 0.012
Family history of premature CVD, n (%) 16 (8.9) 7 (6.7) 6 (11.3) 3 (14.3) NS
Family history of T2DM, n (%) 37 (20.7) 16 (15.2) 15 (28.3) 6 (28.6) NS
Hypertension, n (%) 49 (27.4) 15 (14.3) 20 (33.7) � 14 (66.7)† <0.001
Dyslipidemia, n (%) 76 (58.5) 24 (36.4) 35 (77.8) � 17 (89.5)† <0.001
Diabetes
Diabetes duration (yrs.) 16 (12–23) 14 (20–22) 18 (15–27) � 20 (15–29)† <0.001
Total insulin doses (UI/kg�day) 0.6
(0.5–0.8)
0.6
(0.5–0.8)
0.7
(0.6–0.8)
0.6
(0.5–0.7)
NS
Microvascular complications, n (%) 68 (38.4) 28 (27.2) 23 (43.4) 18 (81.0) †,‡ <0.001
Retinopathy, n (%) NS
None 138 (77.1) 86 (81.9) 40 (75.5) 12 (57.1)
Non-proliferative 20 (11.2) 9 (8.6) 6 (11.3) 5 (23.8)
Proliferative 21 (11.7) 10 (9.5) 7 (13.2) 4 (19.1)
Nephropathy, n (%) 41 (23.2) 14 (13.6) 15 (28.3) 4 (19.1)† <0.001
Peripheral neuropathy, n (%) 7 (3.9) 1 (1.0) 3 (5.7) 3 (14.3)† 0.011
Anthropometric measurements
Weight (kg) 71.7 (13.0) 69.8 (12.4) 75.2 (14.3)� 72.0 (10.7) 0.045
BMI (kg/m2) 25.4 (3.7) 24.3 (3.2) 26.6 (3.8)� 27.8 (4.4)† <0.001
Waist-to-hip ratio 0.88
(0.81–0.94)
0.84
(0.77–0.90)
0.93
(0.86–0.99) �
0.94
(0.90–0.98)†
<0.001
Blood pressure
SBP (mmHg) 125.6 (12.1) 121.8(11.0) 128.8(11.2)� 136.9(10.7)†,‡ <0.001
DBP (mmHg) 72.0 (8.9) 70.1 (8.2) 74.4 (8.7)� 75.7 (10.1)† 0.002
MAP (mmHg) 89.9 (9.1) 87.3 (8.4) 92.5 (8.5) 96.1 (9.6) <0.001
Laboratory parameters
Fasting plasma glucose (mmol/L) 8.2 (3.8) 7.8 (3.5) 8.4 (3.8) 9.5 (4.5) NS
HbA1c (%) 7.8 (1.0) 7.6 (1.0) 8.0 (1.0) 8.5 (1.1)
† <0.001
HbA1c (mmol/mol) 61.8 (11.4) 59.2 (11.0) 63.7 (10.5) 69.9 (11.6)
Urinary ACR (mg/g) 4.7
(2.7–10.6)
4.1
(2.4–7.7)
6.1
(3.0–9.8)
14.0
(5.3–54.0)†,‡
<0.001
Total cholesterol (mmol/L) 4.6 (4.1–5.2) 4.5 (4.0–5.1) 4.7 (4.3–5.2) 5.1 (4.4–5.8) NS
HDL-cholesterol (mmol/L) 1.7 (1.3–2.0) 1.6 (1.3–1.9) 1.7 (1.4–2.1) 1.7 (1.5–2.2) 0.073
LDL-cholesterol (mmol/L) 2.5 (2.1–2.9) 2.5 (2.2–2.9) 2.4 (2.1–2.8) 2.6 (2.3–3.1) NS
Triglycerides (mmol/L) 0.73
(0.60–0.90)
0.72
(0.54–0.88)
0.73
(0.63–0.90)
0.76
(0.68–1.1)†
NS
Insulin resistance
eGDR (mg/kg/min) 8.6
(6.1–10.0)
9.5
(8.4–10.4)
6.9
(5.4–8.8)�
5.6
(4.1–6.8)†,‡
<0.001
Arterial stiffness
aPWV (m/s) 7.5 (1.9) 6.4 (1.0) 8.4 (1.3)� 10.3 (2.5)†,‡ <0.001
Data are given as percentages, mean (SD) or median (interquartile range). CVD: cardiovascular disease. T2DM: type 2 diabetes. BMI: body mass index. WHR: waist-to-
hip ratio. SBP: systolic blood pressure. DBP: diastolic blood pressure. MAP: mean arterial pressure. ACR: urinary albumin to creatinine ratio. eGDR: estimation of
glucose disposal rate. aPWV: aortic pulse wave velocity.
�p<0.05 for moderate-risk compared with low-risk
†p < .0.05 for high-risk compared with low-risk and
‡p<0.05 for high-risk compared with moderate-risk.
https://doi.org/10.1371/journal.pone.0220206.t001
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In univariate analyses, age (r = 0.941; p<0.001), smoking habit (r = 0.228; p = 0.006), family
history of T2DM (r = 0.184; p = 0.014), arterial hypertension (r = 0.415; p<0.001), SBP
(r = 0.439; p<0.001), DBP (r = 0.334; p<0.001) and MAP (r = 0.415; p<0.001), dyslipidemia
(r = 0.518; p<0.001), total cholesterol (r = 0.187; p = 0.033), diabetes duration (r = 0.274;
p<0.001), chronic complications (r = 0.359; p<0.001), diabetic nephropathy (r = 0.360;
p<0.001), peripheral neuropathy (r = 0.201; p = 0.007), BMI (r = 0.307; p<0.001), WHR
(r = 0.563; p<0.001), HbA1c (r = 0.252; p<0.001) and aPWV (r = 0.777; p<0.001) were posi-
tively associated with the ST1RE score (Fig 1, panel B).
To evaluate the potential role of aPWV for predicting cardiovascular risk according to the
ST1RE, we developed one regression model for moderate/high-risk patients and another
model for high-risk patients. aPWV was positively associated both with moderate/high- and
high-risk according to the ST1RE, with an odds ratio (OR) of 4.73 (95% confidence interval
[CI] 3.00–7.45; p<0.001) and 2.28 (95%CI: 1.66–3.12; p<0.001), respectively. The C-statistic
of aPWV was 0.914 (95%CI: 0.873–0.95) for predicting moderate/high-risk and 0.879 (95%CI:
0.809–0.948) for high-risk according to the ST1RE (Fig 2). The best cut-off points of aPWV
were 7.3 m/s (sensitivity: 86% and specificity: 83%) and 8.7 m/s (sensitivity: 76% and specific-
ity: 86%) for moderate/high and high-risk, respectively.
Discussion
The main finding of the present study is that arterial stiffness is highly correlated with the
scores obtained from the ST1RE in patients with T1DM and without previous CVD. In addi-
tion, we have identified two cut-off points of arterial stiffness that can clearly discriminate
moderate/high- and high-risk T1DM patients, which could be of significant value in clinical
practice.
aPWV predicts cardiovascular events and total and cardiovascular mortality in the general
population, in the elderly, and in patients with hypertension, end-stage renal failure or T2DM
[6]. The independent predictive value of arterial stiffness has been proven after adjustment for
classical cardiovascular risk factors and its estimation has also been demonstrated to improve
cardiovascular risk prediction beyond the Framingham Risk Score [9, 10]. This suggests that
measurement of arterial stiffness could add value to the classical cardiovascular risk factors in
Fig 1. A. Comparison of aortic pulse wave velocity (aPWV) for the Steno Type 1 Risk Engine (ST1RE) low- (<10%), moderate- (10–20%) and high-risk (�20%) groups
(�p<0.05 for multiple comparison). B. Spearman correlation coefficient for the association between aPWV and ST1RE risk score.
https://doi.org/10.1371/journal.pone.0220206.g001
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the prediction of cardiovascular risk. A possible explanation for this is that arterial stiffness inte-
grates the damage of cardiovascular risk factors (known and unknown) on the aortic wall since
birth, whereas classical cardiovascular risk factors can fluctuate over time, and hence their value
at any given time may not reflect their real impact on arterial wall damage over the lifetime [23].
It has been reported that the currently used risk scores (designed for general or T2DM popu-
lations) clearly underestimate cardiovascular risk in the T1DM population [11, 12]. Accord-
ingly, it is of special interest to develop specific cardiovascular risk models for these patients [2].
Three different risk scores have been recently developed for predicting CVD in T1DM, which
differ in several aspects such as the number (between 4 and 11) and type of variables employed,
and the population used for developing the models. However, none of them have been used thus
far in routine clinical practice [2, 24]. The first risk score was developed in a childhood-onset
T1DM cohort [25]; the second one, based on the Swedish National Diabetes Register [26],
included patients with previous cardiovascular events (including patients in primary and sec-
ondary prevention), and the third one, the ST1RE [12], was developed and validated in two
cohorts of adult patients with T1DM without established CVD (similar to our patient group).
A possible reason for the high correlation between arterial stiffness and the ST1RE score
could be the similarities between the two cohorts in terms of age (41.2 years vs. 42.2 years),
gender distribution (50.8% vs. 54.2% of males) and duration of T1DM (16.0 years vs. 16.6
years). Given our results and the fact that arterial stiffness has the potential to improve the
value of classical cardiovascular risk factors for predicting CVD, we believe that its assessment
could be of great value in clinical practice, improving the cardiovascular risk stratification and
the follow-up of patients with T1DM without established CVD.
In this study, we found that the discrimination of aPWV was excellent with a C-statistic of
0.914 for predicting moderate/high-risk, and 0.879 for high-risk. In addition, we identified two
potential cut-off points of arterial stiffness that can clearly discriminate moderate/high- (7.3m/
s) and high-risk (8.7m/s) T1DM patients, which could be of significant value in clinical practice.
Nevertheless, we acknowledge that one important limitation of aPWV is how distance is
assessed. In our setting, we used the subtraction of suprasternal notch-to-carotid distance from
the suprasternal notch-to-femoral distance, as previously described [14, 23]. Prior studies com-
paring the distance measured using magnetic resonance imaging (a direct measure of aortic stiff-
ness) have shown that the subtraction method underestimates the distance measurements and
Fig 2. ROC curves for aPWV to identify cardiovascular risk according to the ST1RE for moderate/high- (panel A) and high-risk groups (panel B).
https://doi.org/10.1371/journal.pone.0220206.g002
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overestimates aPWV. For this reason, some authors have recently proposed new distance mea-
surements that would improve the estimation of the carotid-femoral path length [27]. Of all cur-
rently used distances, the 80% of the direct carotid-femoral distance (common carotid artery—
common femoral artery × 0.8) has been proposed as the most accurate. Consequently, a new stan-
dard cut-off value aPWV of 10m/s has been proposed as indicative of subclinical organ damage
and increased risk for cardiovascular events [28], instead of the previously established cut-off
value of 12m/s proposed in 2007 [29]. Thus, it should be acknowledged that the method used to
measure the distance needs to be taken into consideration when interpreting our results, as it can
clearly modify our proposed cut-off points derived from the ROC curves.
We also acknowledge that prospective studies are needed to investigate the potential role of
arterial stiffness for predicting cardiovascular events in subjects with T1DM. To the best of our
knowledge, only one such study has attempted to evaluate the relationship between central
arterial stiffness and the prediction of cardiovascular events in T1DM. This study showed that
central pulse pressure as a measure of central arterial stiffness was more strongly associated
with the prediction of cardiovascular events than the augmentation index (an indirect measure
of arterial stiffness), but no data on aPWV were reported [30]. We are aware that estimated
10-year CVD risk is an imperfect end-point to test the potential predictive role of aPWV, as it
does not represent true disease status and there is the possibility to misclassify patients into the
wrong risk group (as in all algorithms designed to predict cardiovascular risk). Also, the valida-
tion of ST1RE was performed for the 5-year data and most participants were Danish. Thus,
additional studies exploring the potential role of arterial stiffness to predict future events and
validated in other populations are needed.
The major limitation of the current study is its cross-sectional design, which makes it
impossible to determine the temporal ordering of the association between arterial stiffness and
cardiovascular events. In addition, the young age and the small sample size (especially in the
high-risk group) could underestimate our results. Nonetheless, it seems reasonable to believe
that this score might add predictive value to the classical cardiovascular risk models. In addi-
tion, the study was observational in design and consequently complete control of all potential
(unknown) confounding factors could not be ensured.
Conclusions
In summary, our study demonstrates that aPWV is highly correlated with the scores obtained
from the ST1RE in a Mediterranean cohort of subjects with T1DM without previous CVD.
We have identified two cut-off points of arterial stiffness that can clearly discriminate moder-
ate/high- and high-risk patients. These cut-offs could be of great interest in clinical practice.
Our findings suggest that measurement of arterial stiffness is a useful tool for detecting sub-
clinical arteriosclerosis and contributes to better cardiovascular prediction in T1DM. Never-
theless, prospective studies are needed to clarify the relationship between arterial stiffness and
macrovascular complications in subjects with T1DM.
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